Extraordinary general meeting in CellCura ASA (CellCura or the Company) will be held Friday 21 November 2014 at 10am at Vika Atrium, Munkedamsveien 45, Entrance A, 5th floor, Oslo. The notice with the agenda and related relevant information is enclosed to this notice.

As previously announced CellCura has not succeeded in establishing a viable long-term financing for the Company. Further, there is currently insufficient interest amongst the Company's shareholders to initiate an equity placement or to provide other types of financing to the Company. Consequently, the Company does not have access to otherwise preferred financing alternatives (e.g. equity placement by way of rights issue or similar).  

The qualified members of the Board of Directors has negotiated a convertible loan agreement with CellCura's largest shareholder Dag Dvergsten AS whereby Dag Dvergsten AS will grant / extend a loan to CellCura on the terms and conditions set out in the enclosed notice. This will give CellCura some more time to work for a sustainable financing and in parallel other strategic alternatives.

The Board of Directors is of the opinion that the terms and conditions for the convertible loan agreement is favourable seen in light of the Company's financial strain. The Board of Directors have in this respect not been able to identify any other alternatives for the Company at this stage. The Board of Directors proposes that the general meeting approves the convertible loan agreement.

Board member Pål Eivind Vegard comments: "We appreciate the support of the Company's largest shareholder despite the critical financial situation of the Company. The Board cannot under the current circumstances see any viable alternative to accepting the proposed convertible loan. We hope that this provision of additional liquidity will help inspire other shareholders, investors and capital providers to contribute to with additional financing for the Company."

The Company is continuously seeking to secure additional financing for the Company. Hence, it is proposed that the general meeting authorises the Board of Directors to enter into additional convertible loan agreements and to issue new shares through share capital increases. For further information, please see the enclosed notice.

Oslo, 30 October 2014

CellCura ASA
Tore Viana-Rønningen
Chief Executive Officer
Phone: + 47 911 08 693

CellCura ASA is dedicated to the development and sales of cell technologies for use in assisted reproductive technology (ART) and stem cell research worldwide, representing improved safety and efficiency compared to traditional technology. CellCura is listed on the Oslo Axess market at the Oslo Stock Exchange (ticker: CELL)

www.cellcura.com

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)


distributed by